Timber Pharmaceuticals Inc (TMBR) |
|
1.91 -0.31 (-13.96%)
|
03-03 16:27 |
|
Open: |
2.17 |
Pre. Close: |
2.22 |
|
High:
|
2.23 |
Low:
|
1.86 |
|
Volume:
|
3,060,063 |
Market Cap:
|
23M |
|
|
|
|
Timber Pharmaceuticals, Inc., formerly BioPharmX Corporation, is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for orphan dermatologic diseases. It is developing treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma. Its pipeline includes TMB-001, TMB-002 and TMB-003. TMB-001 is a topical isotretinoin, which is being developed for the treatment of moderate to severe subtypes of CI. TMB-002, a topical rapamycin, is being developed for the treatment of facial angiofibromas (FAs) in TSC. TMB-003 is a topical / subcutaneous ET-A receptor antagonist, which is being developed for localized scleroderma. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.283 - 2.294 |
2.294 - 2.305 |
|
Low:
|
1.99 - 2.003 |
2.003 - 2.015 |
|
Close:
|
2.194 - 2.216 |
2.216 - 2.238 |
|
Technical analysis |
as of: 2021-03-03 4:10:07 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 2.77 One year: 3.68 |
| Support: |
Support1: 1.12 Support2: 0.93 |
| Resistance: |
Resistance1: 2.37 Resistance2: 3.15 |
| Pivot: |
2.16  |
| Moving Average: |
MA(5): 2.04 MA(20): 1.98
MA(100): 1.21 MA(250): 2.06 |
| MACD: |
MACD(12,26): 0.19 Signal(9): 0.23 |
| Stochastic oscillator: |
%K(14,3): 42.52 %D(3): 40.96 |
| RSI: |
RSI(14): 52.29 |
| 52-week: |
High: 10.44 Low: 0.67 Change(%): -63.9 |
| Average Vol(K): |
3-Month: 755636 10-Days: 569295 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.TMBR has closed above bottom band by 34.2%. Bollinger Bands are 124.8% wider than normal. The large width of the bands suggest high volatility as compared to TMBR's normal range. The bands have been in this wide range for 16 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 02 Mar 2021
Do Analysts Agree Tuesday on Timber Pharmaceuticals Inc (TMBR) Stock's Target Price? - InvestorsObserver
Mon, 01 Mar 2021
Should You Buy Timber Pharmaceuticals Inc (TMBR) Stock on Monday? - InvestorsObserver
Wed, 24 Feb 2021
Premarket Mover: Timber Pharmaceuticals Inc (TMBR) Up 9.76% - InvestorsObserver
Mon, 22 Feb 2021
Timber Pharmaceuticals Inc (TMBR) Stock Declines -19.15% This Week; Should You Buy? - InvestorsObserver
Thu, 11 Feb 2021
Timber Pharmaceuticals Inc (TMBR) Up 27.13% in Premarket Trading - InvestorsObserver
Tue, 02 Feb 2021
Should You Buy Timber Pharmaceuticals Inc (TMBR) Stock Tuesday? - InvestorsObserver
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Outperform |
Price to Earnings: |
Outperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
12 |
| Shares Float (M) |
4 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
|
|
Shares Short (K)
|
850 |
|
Shares Short P. Month (K)
|
792 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
-5341.09 |
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.254 |
|
Sales Per Share
|
0.029 |
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-6 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
66.63 |
|
Price to Cash Flow
|
-3.77 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
